chrisvoncsefalvay/vaers-outcomes huggingface dataset:
arm is itching; sore arm; swollen lymph node on injection site arm; This spontaneous case was reported by a patient and describes the occurrence of PRURITUS (arm is itching), PAIN IN EXTREMITY (sore arm) and VACCINATION SITE LYMPHADENOPATHY (swollen lymph node on injection site arm) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRURITUS (arm is itching), PAIN IN EXTREMITY (sore arm) and VACCINATION SITE LYMPHADENOPATHY (swollen lymph node on injection site arm). At the time of the report, PRURITUS (arm is itching), PAIN IN EXTREMITY (sore arm) and VACCINATION SITE LYMPHADENOPATHY (swollen lymph node on injection site arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.   Treatment information was not provided.
Sore arm with all 4; This spontaneous case was reported by a non-health professional and describes the occurrence of PAIN IN EXTREMITY (Sore arm with all 4) in a patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7148B) for COVID-19 prophylaxis.     The patient's past medical history included Breast cancer in October 2021. Concurrent medical conditions included Sulfonamide allergy (Sulfa), Drug allergy (Zofran) and Psoriatic arthritis.    On 04-Nov-2022 at 12:00 PM, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Sore arm with all 4). At the time of the report, PAIN IN EXTREMITY (Sore arm with all 4) outcome was unknown.            Concomitant medication was not reported.  Patient received monovalent doses of Moderna. Dose 1 on 28-Dec-2020; Batch/Lot No: 039K20A. Dose 2 on 29-Jan-2021; Batch/Lot No: 012L20A and Dose 3 on 02-Sep-2021; Batch/Lot No: 002F21A.  Patient received unspecified drug from 14-AUG-2023 to 18-AUG-2023 for treatment of COVID-19.  Treatment medication was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-738998 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-738998:Monovalent case
PERIPHERAL NEUROPATHY ACUTE STROKE DUE TO OCCLUSION OF UNSPECIFIED ARTERY
Approximately one week post vax pt developed a fever of 103, subsequently pt experienced nasal congestion, cough, and pain in upper and lower extremities.
Joint pain, muscle aches, pain. Deep, aching pain and muscle wasting in the upper arm(s). Elbow, Ligaments, no cartilage, Family Dr & Orthopedic.
Tonic Seizure lasted 1 min about 2 mon after giving the 0.5 ml IM shot of DT.Tdiphteria-tetanus)
This spontaneous report as received from a nurse refers to a 17-year-old patient of unknown gender. No information regarding patient's pertinent medical history, drug reactions, allergies, concomitant medications was provided. On 30-JAN-2019, the patient was vaccinated with a partial dose of GARDASIL 9, lot number R024264, expiration date 29-10-2019 (dose, dose number, route of administration were not provided) for prophylaxis. The nurse reported that during vaccine administration on 30-JAN-2019, after the dose was drawn from the vial into a syringe, the hub of the needle separated from the syringe and some of the medicine came out of the syringe. As a result, a partial dose was given to the patient. There was no adverse event reported.
Patient feels Hot/Cold, Arm is sore,  Weak and tired,  Sore throat.
Patient given vaccines and PPD test 07/19/2006.  Returned to clinic 07/21/2006 for PPD reading and left upper arm noted to be red, swollen and warm.  Seen by above medical doctor who diagnosed cellulitis, ordered ice packs to arm and KEFLEX 125 mg, by mouth every 6 hours for 10 days.  Child returned to see medical doctor 07/28/2006 and left arm normal.
weakness under his shoulder; pain under his shoulder; Parson Turner Syndrome  (neuritis); Parson Turner Syndrome  (neuritis); experience arm pain; difficulty moving his arm; This is a spontaneous report received from a contactable physician. The physician reported similar events for two patients, this is the first of two reports.   A 20-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration at 20 years old on 17Apr2021 (Batch/Lot number was not reported) at single dose for covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously received the first dose of bnt162b2 on an unspecified date for covid-19 immunization. Caller reported that he had a patient who received his Pfizer vaccine, second dose last Saturday (17Apr2021). He reported that on Monday (19Apr2021) he continued to experience arm pain followed by difficulty moving his arm. Now he was requiring a sling, had been prescribed Toradol and Steroids but was not doing any better. He was having continued weakness and pain under his shoulder. Caller was asking for documentation or studies that have been done to determine if the vaccine has any relationship with Parson Turner Syndrome (neuritis) and recommendations for management. He asked to speak with a Pfizer Neurologist. Caller reported that the patient was being seen by an orthopedist, MD. Caller was requesting urgent escalation of his inquiry for further investigation into a relationship between the covid vaccine and Parson Turner Syndrome (neuritis). The outcome of the events was unknown.  No Follow-up attempts are needed. Information about lot/batch number cannot be obtained.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021441207 Same reporter/drug/AE, different patient
Stabbing sensation in her heart, chest area; Stabbing sensation in her heart, chest area; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A female patient received bnt162b2 (BNT162B2), administration date 29Jan2022 (Batch/Lot number: unknown) as dose number unknown (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (MANUFACTURER UNKNOWN,dose number unknown), for COVID-19 Immunization. The following information was reported: ANGINA PECTORIS (medically significant), CHEST PAIN (medically significant) all with onset 29Jan2022, outcome "unknown" and all described as "Stabbing sensation in her heart, chest area". Additional Context:  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Local injection site rash, pruritis, blanchable erythema, warmth  treated with topical hydrocortisone cream and Benadryl po x1.
Pt vax;  later, PPD testing was pos in inject arm & neg in other arm.
Pain in the injection site; Soreness in lower part of his leg; This is a spontaneous report from a Pfizer-sponsored program. A contactable consumer (patient) reported that a 75-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported.  The patient previously took acetylsalicylic acid (ASPIRIN) 36 hours before the 1st shot of vaccine. Patient called in because he took acetylsalicylic acid 36 hours before the 1st shot of vaccine. Asking how much it will effect the efficacy. Mentioned he felt a little bit of pain in the injection site and soreness in lower part of his leg an unspecified date. The outcome of the events was unknown.   Information on the lot/batch number has been requested.
Client received third dose this day. at 1127am client complained of dizziness, headache, and numbing of lips 1128 am: NP, site lead, and EMT contacted.  NP assessed client.   Client with history of HTN (last BP medication taken last night).  Last taken Fibromyalgia medication last night.  Denies fillers.  NP assessed throat and was clear.  Client with intermittent numbness to lips.    Facial test with eyes closed, passed.  Tongue moved side to side.  Strength test to Bilateral extremities 5/5.  Warm and dry to touch 1130 am: client layed down with legs elevated on chair.  BP: 162/101, Pulse 87, O2 sat 98 % RA. 1134 am: NP informed site lead to contact 911. 1138 am: BP 168/83, P: 89, O2 sat 99 % RA.  Blood glucose 100. 1140 am: client feeling more alert.  denies headache denies chest paint 1142 am: Paramedics arrived on site.  NP/site director indorsed care to paramedics. 1144 am: client brought to ambulance for assessment by paramedics 1205 pm: client left with paramedics to Medical Center of additional evaluation.  Client significant other was informed
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 21-MAR-2016, the patient was vaccinated with an improperly stored dose of GARDASIL 9 (strength: 0.5ml)(lot # L036245, expiration date 09-FEB-2018). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion for three times. The total cumulative excursion time (hour), the lowest recorded temperature (Fahrenheit degree) and the type of excursion (refrigerator/freezer)(R/F) for the first and second time were 16, 29 and R; 212, 34 and R. The total cumulative excursion time (hour), the highest recorded temperature (Fahrenheit degree) and the type of excursion (refrigerator/freezer)(R/F) for the third time were 24, 49 and R. The storage criteria was R. This is one of several reports received from the same source. Additional information has been requested.
Patients arm swelled up around the injection site, became red, and hot to the touch in the evening after given the shot at 3:13pm. By 11 am the next day her arm was not as swollen though still red and hot to the touch. Patient was told to monitor the swelling and if swelling was still occuring at day 7 to seek doctor attention.
Information has been received from a registered nurse concerning a 76 year old white female with no history of allergies and a sore throat who on 11/6/02 (previously reported as 10/4/02) was vaccinated with a first dose of pneumococcal vaccine 23 polyvalent (lot # 644103/0710M) in her right deltoid. Concomitant therapy included erythromycin. On 11/7/02 (previously reported 11/6/02 at an office visit), the nurse noted the patient had developed a cellulitis like reaction described by the patient as soreness at the area of the injection site. The nurse reported that the area of the patient's right deltoid was erythematous, tender, and painful and that the patient was diagnosed with a local reaction. The patient developed swelling, redness, and a 17x17cm erythematous, warm indurated area of her right deltoid. The nurse also provided information regarding other patients' experiences. The patient sought medical attention at her physician's office. Additional information is not expected.
Information has been received from a female patient who on an unspecified date was vaccinated with a dose of PNEUMOVAX 23. Subsequently the patient had an allergic reaction to a pneumonia shot and her lymph nodes filled up. It was unknown if the patient sought any medical attention. At the time of the report, the patient's outcome was unknown. The reporter disconnected the phone before verifying it the shot was PNEUMOVAX 23 or not. No further information is available.
1st shot on 1/5/2021 felt really tired and fatigued.  Woke up at 5:30am on 1/6/2021 with chills and a headache.  Some light swelling and soreness at the injection site on the left arm. 2nd shot on 1/26/21 @ 4:15pm.  Right arm swollen, muscle very sore and tight feeling.  Some bruising.  Half dollar sized knot at the inject site.
Severe swelling; Redness; Pain; Discomfort; This is a spontaneous report from a contactable pharmacist via a Pfizer sales representative. A female patient of an unspecified age received pneumococcal 13-valent conjugated vaccine (diphtheria crm197 protein) (PREVNAR 13, lot number and expiration date were not reported), via an unspecified route of administration on an unspecified date at single dose for immunisation.  The patient medical history and concomitant medications were not reported.  The patient experienced severe swelling, redness, pain and discomfort on an unspecified date.  The outcome of the events was unknown.  Information on the batch number has been requested.
This spontaneous report as received from a pharmacist refers to a 55 year old male patient. The patient was being treated for an unspecified rash on unspecified places on the body, with unspecified medications, prior to receiving ZOSTAVAX. There was no history of drug allergies or reactions. On 09-DEC-2015 the patient was vaccinated with ZOSTAVAX lot # L027322 and expiry date of 21-OCT-2016 at 0.65 ml, subcutaneous. On 12-DEC-2015, the patient came back to the pharmacy because, on an unspecified date in December 2015, after he received the ZOSTAVAX, the patient developed "swelling and a blistering rash with dried, yellow pus" at the injection site. No lab tests were performed. No treatment was received in response to the events. The outcome of the events was not resolved. Causality assessment was not provided. Additional information has been requested.
Information has been received from a nurse referring to multiple unknown patients of unknown age and gender. Information about pertinent medical history and drug allergies was not provided. On multiple unspecified dates, multiple unknown patients were administered improperly stored ROTATEQ (lot#: M029252, expire date: 14-MAR-2018, dose and frequency were unknown) for prophylaxis. The temperature of storage for ROTATEQ was 22 Celsius for 5 minutes. This alarm happened while plugging in the Data logger. No adverse effects reported. No product quality complaint was involved. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1612USA003676: US-009507513-1612USA004316: US-009507513-1612USA004315: US-009507513-1612USA004317.
Body aches left arm was hard to use for about a day. Severe sinus pressure headache. Very tired. Cold all the time. The worst symptom is that my head feels like it?s going to blow up I tookAdvil a couple times and that didn?t help with the pressure in my head also feel a little lightheaded probably because of the headache
For one week nausea, chills, no appetite extremely fatigued, weak - no energy, fever (ears, teeth, back, neck spine hurt) (nose-severe pain and burning. Energy level down after 3 weeks. Dose too strong for 130 pound woman?) After 3 weeks plus - still do not feel ok. I would never get this shot again.
Patient stated that she had a fever (up to 101.1 F) on day of vaccine but when asked if she was sick on day vaccine was administered, she noted denying being sick. During exam was noted to have rhinosinusitis and was started on AUGMENTIN.
body aches; chills; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program. The reporter is the patient.  A 62 year-old male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. Relevant medical history included: "felt horrible after", start date: 2020 (unspecified if ongoing), notes: after he received his Shingles vaccines he "felt horrible after". The patient's concomitant medications were not reported. The following information was reported: PAIN (non-serious), outcome "recovered", described as "body aches"; CHILLS (non-serious), outcome "recovered", described as "chills".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
One day post vax pt experienced numbness in right arm and right side., large lump in chin area. Pt was seen in ER and prescribed Augmentin. Two weeks later on return appointment there was no numbness or swelling.
Headaches; This case was reported by a other health professional via sales rep and described the occurrence of headache in an unspecified number of patients who received Men B NVS (Bexsero) for prophylaxis.   On an unknown date, the patient received Bexsero at an unknown dose. On an unknown date, unknown after receiving Bexsero, the patient experienced headache. On an unknown date, the outcome of the headache was unknown.   It was unknown if the reporter considered the headache to be related to Bexsero.  Additional details were provided as follows: The age at vaccination was not applicable for this report. The healthcare professional stated that he has seen headaches reported frequently after having been vaccinated with Bexsero.
contracted Covid and had been vaccinated with Comirnaty; contracted Covid and had been vaccinated with Comirnaty; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A male patient received BNT162b2 (COMIRNATY), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "contracted Covid and had been vaccinated with Comirnaty".  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Initial solicited report received from an investigator in a trial on 02 March 2017. A 22-year-old male subject with no significant medical history reported. The subject received concomitant medication with Japanese Encephalitis on 2 November 2015, Influenza on 15 October 2015 and Anthrax 02 November 2015. The subject received a dose of ACAM2000, (lot number and site of administration not reported) on 09 November 2015. On 18 November 2015, 09 days after vaccination the subject was diagnosed with pericardium, unspecified. On 24 November 2015, 15 days after vaccination the subject was diagnosed with Myocarditis, unspecified. And on 02 December 2015, 24 days after vaccination the subject was diagnosed with acute myocarditis, unspecified. The lab data included 19 November 2015, the Troponin I was 00.27, on 18 November 2015, ECG was abnormal, on 19 November 2015, Echocardiogram were normal, on 01 December 2015 MRI (heart) was abnormal, MRI (brain and spinal cord) and Lumbar puncture (spinal tap) were not performed. Treatments were not reported. The subject's outcome was not reported. Relationship to investigational product according to company: associated. Additional information will be requested from the investigator. Note: There is no reporter causality assessment as this is a safety surveillance (data mining, non-interventional) study; Sender's Comments: This case involves a 22-year-old male who developed acute myocarditis unspecified and unspecified disease of pericardium with favorable temporal association post vaccination with ACAM200. Subject had other confounding factors as multiple concomitant administrations of vaccines including Japanese encephalitis, influenza and anthrax vaccines. Myocarditis is a listed adverse event that may occur following vaccination with live vaccinia virus smallpox vaccine. Based on data available, role of study vaccine cannot be ruled out.
diarrhea, excess bowel movement just like colonoscopy flush; reaction at site of injection on his arm; A spontaneous report was received from a non-health professional concerning a 79-year-old, male consumer who received Moderna's COVID-19 vaccine and developed diarrhea and a reaction at the injection site.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 29 Dec 2020 at 10:00 AM, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Lot number: 026L20A) intramuscularly for prophylaxis of COVID-19 infection.     On 29 Dec 2020, twelve hours post vaccination, the patient began to experience excess bowel movement which was more like colonoscopy flush. The patient reported diarrhea was also interfering in his day to day activities. He also developed a reaction at site of injection on his arm. No treatment information was provided.  Action taken with the second dose of mRNA-1273 in response to the events was not reported.  The outcome for the events, diarrhea and a reaction at the injection site was unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the onset date of the reported events, a causal relationship cannot be excluded.
After receiving the vaccination I had tingling in my left arm.  I had a rapid heartbeat with skipped beats that took a long time to subside. Saturday and Sunday they would come in spurts. Medication was taken to help. It helped some, however the skipped beats and the rapid heart rate continued. By Monday, the 8th my heart rate was back to normal.
06/04/02 - Right thigh swollen with 4-5 cm redness, 1.5 times size of left thigh, 06/05/02 - Right thigh decreased swelling, 3 cm redness symptoms improving, playful
Patient presented to the ED on 1/6 for dizziness, hypercalcemia, DCIS and was subsequently hospitalized 1/7 within 6 weeks of receiving COVID vaccination.
I unfortunately have some concerns after getting the vaccine, and am hoping to hear both from someone who can disprove my concerns and any mamas to be with similar issues. I had a 14-week us and baby was measuring within a few days of my predicted due date. I got the first Pfizer shot at about 15 weeks. Sore arm and mild fever for two days, nbd. Second shot at 19 weeks. Mild fever for four days. Also no big deal. But I just had my 20 week us yesterday and am now measuring about three weeks behind. Had to follow up with maternal/fetal at the hospital for more analysis, and they confirmed I am measuring below 5th percentile for 20 weeks. Anatomically, everything looks okay, no defects, and they cannot find a source for the stunted growth, so this is good news. But I?m just to ?wait and see? for three weeks now how my growth trajectory looks. Given the ironic timeline of the growth delay with the timing of the vaccines I asked the doc today whether it?s pure coincidence or possibly related, and she assured me there?s no reason to believe it?s related, but she can understand my concern given the timeline. I understand my growth issue could be related to any number of things, but I can?t shake the coincidence of the vaccine timing with the growth slowing. I will be returning to Hospital in three weeks for a follow up on the IUGR issue and an updated growth projection.